Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron-Sanofi’s Dupixent recommended by CHMP for EU approval to treat CSU in young children with ongoing symptoms despite treatment: Tarrytown, New York Wednesday, March 4, 2 ...

BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...

Okay. I think we can get started. Good morning, everyone, and welcome to Miami. Very happy to have Regeneron here with us today to kick off the morning here at the Barclays Global Healthcare ...

Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...

Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.

Timo Lassmann is at The Kids Research Institute Australia and the UWA Centre for Child Health Research, The University of Western Australia, Nedlands, Western Australia 6009, Australia. Read the paper ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

Chronic liver disease is long-term liver damage that worsens over months to years. Ongoing inflammation can lead to fibrosis, which can progress to permanent scarring called cirrhosis. Common causes ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...